Top

Published in:

01-08-2016 | Original Article

The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey

Authors: Ömer Nuri Pamuk, Salim Dönmez, Gökçe Büşra Calayır, Gülsüm Emel Pamuk

Published in: Clinical Rheumatology | Issue 8/2016

Abstract

Epidemiological data about antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is very limited. Until now, there has been no study about the epidemiology of AAV in Turkey. In this study, we evaluated the frequency of AAV in the northeastern part of Turkey. The general clinical features of patients diagnosed with AAV at our center within the last 10 years (2004–2014) were retrospectively recorded down. The incidence rates and the prevalence per 1,000,000 population aged ≥16 years were calculated. In addition, we evaluated the clinical features and survival rates of AAV patients. There were 30 patients with granulomatous polyangiitis (GPA), 15 with microscopic polyangiitis (MPA), and 5 with eosinophilic polyangiitis (EGPA). The overall prevalence of AAV in our region was 69.3/1,000,000 in individuals ≥16 years. Males had a similar prevalence (73.2/1,000,000) with females (65.4/1,000,000). The mean annual incidence rate was 8.1/million for all AAV. The annual incidence of AAV in females was 6.9/million; in males, it was 9.2/million. The annual incidence for GPA was calculated as 4.8/1,000,000, the incidence for MPA was 2.4/1,000,000, and the incidence for CSS was 0.8/1,000,000. Ten-year survival of patients with AAV was 65.3 %. The only independent poor prognostic factor in Cox’s multivariate analysis was advanced age at the time of diagnosis (OR 7.5, 95 % CI 10.6–526, p = 0.043). The frequency of all AAV in northwestern Turkey was similar to that in southern Europe; however, it was lower than the frequency in Northern Europe.

Gibelin A, Maldini C, Mahr A (2011) Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med 32:264–273CrossRefPubMed

Piram M, Maldini C, Mahr A (2012) Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. Curr Opin Rheumatol 24:193–200CrossRefPubMed

Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG et al (2011) Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) 50:1916–1920CrossRef

Cao Y, Schmitz JL, Yang J, Hogan SL, Bunch D, Hu Y et al (2011) DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol 22:1161–1167CrossRefPubMedPubMedCentral

Fujimoto S, Uezono S, Hisanaga S, Fukudome K, Kobayashi S, Suzuki K et al (2006) Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 1:1016–1022CrossRefPubMed

Haugeberg G, Bie R, Bendvold A, Larsen AS, Johnsen V (1998) Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 17:364–368CrossRefPubMed

Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL (2005) Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 53:93–99CrossRefPubMed

Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J (2003) The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 49(3):388–393CrossRefPubMed

Gatenby PA, Lucas RM, Engelsen O, Ponsonby AL, Clements M (2009) Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum 61:1417–1424CrossRefPubMed

10.

Mahr A, Guillevin L, Poissonnet M, Aymé S (2004) Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 51:92–99CrossRefPubMed

11.

Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007) Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 46:1329–1337CrossRef

12.

Gibson A, Stamp LK, Chapman PT, O’Donnell JL (2006) The epidemiology of Wegener’s granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford) 45:624–628CrossRef

13.

Mahr AD, Neogi T, Merkel PA (2006) Epidemiology of Wegener’s granulomatosis: lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol 24(2 Suppl 41):S82–S91PubMed

14.

Scott DG, Bacon PA, Elliott PJ, Tribe CR, Wallington TB (1982) Systemic vasculitis in a district general hospital 1972–1980: clinical and laboratory features, classification and prognosis of 80 cases. Q J Med 51:292–311PubMed

15.

Andrews M, Edmunds M, Campbell A, Walls J, Feehally J (1990) Systemic vasculitis in the 1980s—is there an increasing incidence of Wegener’s granulomatosis and microscopic polyarteritis? J R Coll Physicians Lond 24:284–288PubMed

16.

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227CrossRefPubMed

17.

Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192CrossRefPubMed

18.

Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107CrossRefPubMed

19.

Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 33:1135–1136CrossRefPubMed

20.

Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100CrossRefPubMed

21.

Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P et al (1994) Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87:671–678PubMed

22.

Merkel PA (2012) Defining disease activity and damage in patients with small-vessel vasculitis. Cleve Clin J Med 79(Suppl 3):S11–S15CrossRefPubMed

23.

Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M (2009) Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 48:1560–1565CrossRef

24.

Herlyn K, Buckert F, Gross WL, Reinhold-Keller E (2014) Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford) 53:882–889CrossRef

25.

Watts RA, Al-Taiar A, Scott DG, Macgregor AJ (2009) Prevalence and incidence of Wegener’s granulomatosis in the UK general practice research database. Arthritis Rheum 61:1412–1416CrossRefPubMed

26.

Faurschou M, Helleberg M, Obel N, Baslund B (2013) Incidence of granulomatosis with polyangiitis (Wegener’s) in Greenland and the Faroe Islands: epidemiology of an ANCA-associated vasculitic syndrome in two ethnically distinct populations in the North Atlantic area. Clin Exp Rheumatol 31(1 Suppl 75):S52–S55PubMed

27.

Koldingsnes W, Nossent H (2000) Epidemiology of Wegener’s granulomatosis in northern Norway. Arthritis Rheum 43:2481–2487CrossRefPubMed

28.

Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA (1996) The epidemiology of Wegener’s granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 39:87–92CrossRefPubMed

29.

Ormerod AS, Cook MC (2008) Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J 38:816–823CrossRefPubMed

30.

Panagiotakis SH, Perysinakis GS, Kritikos H, Vassilopoulos D, Vrentzos G, Linardakis M et al (2009) The epidemiology of primary systemic vasculitides involving small vessels in Crete (southern Greece): a comparison of older versus younger adult patients. Clin Exp Rheumatol 27:409–415PubMed

31.

Takala JH, Kautiainen H, Malmberg H, Leirisalo-Repo M (2008) Incidence of Wegener’s granulomatosis in Finland 1981–2000. Clin Exp Rheumatol 26(3 Suppl 49):S81–S85PubMed

32.

Dadoniene J, Kirdaite G, Mackiewicz Z, Rimkevicius A, Haugeberg G (2005) Incidence of primary systemic vasculitis in Vilnius: a university hospital population based study. Ann Rheum Dis 64(2):335–336CrossRefPubMedPubMedCentral

33.

Hissaria P, Cai FZ, Ahern M, Smith M, Gillis D, Roberts-Thomson P (2008) Wegener’s granulomatosis: epidemiological and clinical features in a South Australian study. Intern Med J 38:776–780CrossRefPubMed

34.

Reinhold-Keller E, Zeidler A, Gutfleisch J, Peter HH, Raspe HH, Gross WL (2000) Giant cell arteritis is more prevalent in urban than rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) 39(12):1396–1402CrossRef

35.

Cakır N, Pamuk Ö, Derviş E, Imeryüz N, Uslu H, Benian Ö et al (2012) The prevalences of some rheumatic diseases in western Turkey: Havsa study. Rheumatol Int 32:895–908CrossRefPubMed

36.

Watts RA, Lane SE, Bentham G, Scott DG (2000) Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 43:414–419CrossRefPubMed

37.

Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DG (2001) Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 60:170–172CrossRefPubMedPubMedCentral

38.

Watts RA, Scott DG (1997) Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol 11:191–217CrossRefPubMed

39.

Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S et al (2008) Renal vasculitis in Japan and the UK—are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 23:3928–3931CrossRefPubMed

40.

Chen M, Yu F, Zhang Y, Zhao MH (2005) Clinical [corrected] and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J 81:723–727CrossRefPubMedPubMedCentral

41.

Li ZY, Chang DY, Zhao MH, Chen M (2014) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol 66:1920–1926CrossRefPubMed

Title: The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey
Authors: Ömer Nuri Pamuk
Salim Dönmez
Gökçe Büşra Calayır
Gülsüm Emel Pamuk
Publication date: 01-08-2016
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 8/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-016-3232-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

Differences in cardiovascular manifestations between ankylosing spondylitis patients with and without kyphosis

Polymorphisms of genes encoding interleukin-4 and its receptor in Iranian patients with juvenile idiopathic arthritis

Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649

Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis

Psoriatic arthritis and psoriasis: differential diagnosis

Pure lupus podocytopathy first presenting as thrombotic thrombocytopenic purpura-like syndrome

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials